Parkinson's drug safinamide refiled in the US
This article was originally published in Scrip
The new drug application (NDA) for Newron Pharmaceuticals' novel Parkinson's disease therapy safinamide has been resubmitted in the US. This follows news last week that the EU's CHMP has granted the drug – which will be marketed as Xadago in Europe – a positive opinion (scripintelligence.com, 22 December 2014). If approved, safinamide will be the first new chemical entity to be approved for the condition in ten years.